East African follow-up data show GSK malaria vaccine efficacy is sustained
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's RTS,S/AS01E candidate recombinant malaria vaccine showed both significant efficacy and sustained activity in an eight to15 months follow up study of nearly 900 children in Kenya and Tanzania, according to a paper published online on 14 January in The Lancet Infectious Diseases.